blue shield of california glp-1 Cross Blue MA to widely stop covering weight loss drugs How Blue Shield Denies Access

These filings remain allegation-based, and the litigation process is designed to test what the evidence shows about risk, labeling, and causation for individual patients who report severe gastrointestinal disease and related complications such as severe abdominal pain and ongoing digestive dysfunction

Implications for obesity drug marketers: Both Lilly and Novo are aiming to expand the GLP-1 weight loss drug market with more accessible, convenient pill options that could broaden uptake

Autotaxin is related to metabolic dysfunction and predicts Alzheimers disease outcomes

Boston Medical Group takes a proactive, data-driven approach to ensure that PT-141 remains both safe and effective for each patient

The direct-to-consumer health-care startup Ro launched a new free tool to help patients determine whether their insurance will cover a class of weight loss and diabetes medications called GLP-1s

This overlap is where caution becomes important